Viz HCM
End-to-end approach for detecting and directing hypertrophic cardiomyopathy (HCM) patients.
Increasing awareness and reach for a potentially fatal, yet commonly missed disease
Potentially fatal, yet commonly missed disease
1 Million people in the US suffer from hypertrophic cardiomyopathy (HCM). Only 20% of those have been diagnosed, with 5 years to diagnosis.
HCM is a leading cause of sudden cardiac death in people under age 35, but if detected early and treated, patients can achieve high quality of life and normal longevity.
End-to-end approach for detecting suspected HCM and directing patients
Viz HCM analyzes all 12-lead ECGs throughout the health system to flag and triage suspected cases to HCM specialists for diagnostic workup, all from the mobile app.
Flag suspected HCM: Review patients identified by AI as having signals of HCM
Follow Up: Direct patients to the HCM specialist for additional workup
Accelerate Diagnosis: View echo images and reports to diagnose HCM
Viz HCM Algorithm Development and Performance
Robust Al Development
- 830k+ ECG exams from 300k individuals
- Covering non-obstructive and obstructive HCM
Diverse Dataset
- Sourced from multiple locations globally
- Included racial & ethnic differences seen in PQRST-wave morphologies
Gold Standard Validated
- Echocardiography
- Cardiac MRIs
Hypertrophic Cardiomyopathy Education Series
Diagnosis, Therapeutics & Enhanced Pathways
A comprehensive program providing valuable insights into evidence-based best practices, using artificial intelligence (AI) for HCM, multidisciplinary care coordination, quality improvement strategies, and development of HCM programs.
Learn more
Resources to Help You Achieve Your Goals
Viz.ai Receives First De Novo Approval by the FDA for AI Algorithm for...
Press & NewsNew artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy SAN FRANCISCO, CA – August 15, 2023 -...
Aug 15, 2023
